Compare · DXCM vs INSP
DXCM vs INSP
Side-by-side comparison of DexCom Inc. (DXCM) and Inspire Medical Systems Inc. (INSP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and INSP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 24.5x INSP ($1.21B).
- Over the past year, DXCM is down 10.6% and INSP is down 69.2% - DXCM leads by 58.6 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 3 for INSP).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Inspire Medical Systems Inc.
- Price
- $76.59+5.15%
- $42.03+1.99%
- Market cap
- $29.57B
- $1.21B
- 1M return
- +25.71%
- -7.87%
- 1Y return
- -10.56%
- -69.20%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2018
- News (4w)
- 26
- 3
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Inspire Medical Systems Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest INSP
- SEC Form SD filed by Inspire Medical Systems Inc.
- Inspire Medical Systems downgraded by BofA Securities with a new price target
- Officer Rondoni John sold $114,302 worth of shares (2,641 units at $43.28), decreasing direct ownership by 9% to 27,165 units (SEC Form 4)
- Officer Rondoni John sold $30,107 worth of shares (700 units at $43.01), decreasing direct ownership by 2% to 29,806 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Inspire Medical Systems Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Inspire Medical Systems Inc.
- Director Mccormick Shawn sold $31,536 worth of shares (696 units at $45.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 27,712 units (SEC Form 4)
- SEC Form 144 filed by Inspire Medical Systems Inc.
- SEC Form S-8 filed by Inspire Medical Systems Inc.
- Inspire Medical Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits